<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218724</url>
  </required_header>
  <id_info>
    <org_study_id>PK-07-068</org_study_id>
    <nct_id>NCT01218724</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck &amp; Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions</brief_title>
  <official_title>An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck &amp; Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective:

      to compare the single dose bioavailability of Torrent's Losartan Potassium and
      Hydrochlorothiazide Tablets 1 × 100/25mg and Hyzaar® Tablets 1 × 100/25mg of Merck &amp; Co.,
      Inc.

      Study Design:

      Randomized, Two-Way Crossover, Single-Dose, Open-Label in 70 healthy human adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence based on AUC parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan Potassium and Hydrochlorothiazide Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The volunteers were excluded from the study based on the following criteria:

               -  Sex: male.

               -  Age: 18 - 45 years. .

               -  Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.

               -  Healthy and willing to participate in the study.

               -  Volunteer willing to adhere to the protocol requirements and to provide written
                  informed consent.

               -  Non-smokers or smoker who smokes less than 10 cigarettes per day

        Exclusion Criteria:

          -  The volunteers were excluded from the study based on the following criteria:

               -  Clinically relevant abnormalities in the results of the laboratory screening
                  evaluation.

               -  Clinically significant abnormal ECG or Chest X-ray.

               -  Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic
                  blood pressure less than 60 mm Hg or more than 90 mm Hg.

               -  Pulse rate less than 50/minute or more than 100/minute.

               -  Oral temperature less than 95°P or more than 98.6°P.

               -  Respiratory rate less than 12/minute or more than 20/minute

               -  History of allergy to the test drug or any drug chemically similar to the drug
                  under investigation.

               -  History of alcohol or drug abuse

               -  Positive breath alcohol test

               -  Recent history of kidney or liver dysfunction.

               -  History of consumption of prescribed medication since last 14 days or OTC
                  medication since last 07 days before beginning of the study.

               -  Volunteers suffering from any chronic illness such as arthritis, asthma etc.

               -  History of heart failure.

               -  HIV, HCV, HBsAg positive volunteers.

               -  Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines,
                  Cocaine positive volunteers based on urine test.

               -  Volunteers suffering from any psychiatric (acute or chronic) illness requiring
                  medications.

               -  Administration of any study drug in the period 0 to 3 months before entry to the
                  study.

               -  History of significant blood loss due to any reason, including blood donation in
                  the past 3 months.

               -  History of pre-existing bleeding disorder.

               -  Existence of any surgical or medical condition, which, in the judgment of the
                  chief investigator and/or clinical investigator/physician, might interfere with
                  the absorption, distribution, metabolism or excretion of the drug or likely to
                  compromise the safety of volunteers.

               -  Inability to communicate or co-operate due to language problem, poor mental
                  development or impaired cerebral function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Torrent BE Centre</name>
      <address>
        <city>Gandhinagar</city>
        <state>Gujarat</state>
        <zip>382 428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

